Case report and literature review: Transient Inab phenotype and an agglutinating anti-IFC in a patient with a gastrointestinal problem

Transfusion

Volumn 46, Issue 9, 2006, Pages 1537-1542

  Yazer, Mark H ^a   Judd, W John ^a   Davenport, Robertson D ^a   Dake, Louann R ^a   Lomas Francis, Christine ^a   Hue Roye, Kim ^a   Powell, Vivien ^a   Reid, Marion ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ANTIBODY; BLOOD GROUP ANTIGEN; CD59 ANTIGEN; DECAY ACCELERATING FACTOR; IFC ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ARTICLE; CASE REPORT; CYTOMEGALOVIRUS INFECTION; FEEDING APPARATUS; FLOW CYTOMETRY; GASTROESOPHAGEAL REFLUX; GROWTH RETARDATION; HEARING DISORDER; HUMAN; IMMUNOPATHOLOGY; INAB PHENOTYPE; MALE; MILK INTOLERANCE; NUTRITIONAL INTOLERANCE; PRESCHOOL CHILD; SOYBEAN; VISUAL DISORDER;

AGGLUTINATION; ANTIGENS, CD55; ANTIGENS, CD59; ERYTHROCYTE MEMBRANE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HUMANS; INFANT; ISOANTIBODIES; MALE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; REVIEW LITERATURE; SEQUENCE ANALYSIS, DNA; TIME FACTORS;

EID: 33748331169     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00933.x     Document Type: Article

References (29)

1. Daniels G. Human blood groups. 2nd ed. Oxford: Blackwell Science; 2002.
2. Reid ME, Powell V, Barnes J, et al. ZENA: a new high prevalence Cromer blood group antigen [abstract]. Transfusion 2004;44(Suppl):26A.
3. Storry JR, Sausais L, Hue-Roye K, et al. GUTI: a new antigen in the Cromer blood group system. Transfusion 2003;43:340-4.
4. Banks J, Poole J, Ahrens N, et al. SERF. a new antigen in the Cromer blood group system. Transfus Med 2004;14:313-8.
5. Storry JR, Reid ME. The Cromer blood group system: a review. Immunohematology 2002;18:95-103.
6. Ivankovic Z, Golubic Cepulic B, Bekavac M, et al. CROV: a new high prevalence Cromer blood group antigen. Transfusion 2005;45(Suppl):122A.
7. Lublin DM. Review: Cromer and DAF: role in health and disease. Immunohematology 2005;21:39-47.
8. Rosse WF, Ware RE. The molecular basis of paroxysmal nocturnal hemoglobinuria. Blood 1995;86:3277-86.
9. Rosse WF, Nishimura J. Clinical manifestations of paroxysmal nocturnal hemoglobinuria. the present state and future problems. Int J Hematol 2003;77:113-20.
10. Levene C, Harel N, Lavie G, et al. A "new" phenotype confirming a relationship between Cra and Tca. Transfusion 1984;24:13-5.
11. Lublin DM, Thompson ES, Green AM, Levene C, Telen MJ. Dr(a-) polymorphism of decay accelerating factor: biochemical, functional and molecular characterization and production of allele-specific transfectants. J Clin Invest 1991;87:1945-52.
12. Reid ME, Mallinson G, Sim RB, et al. Biochemical studies on the red blood cells from a patient with the Inab phenotype (decay accelerating factor deficiency). Blood 1991;78:3291-7.
13. Lublin DM, Mallinson G, Poole J, et al. Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes. Blood 1994;84:1276-82.
14. Daniels GL, Tohyama H, Uchikawa M. A possible null phenotype in the Cromer blood group complex. Transfusion 1982;22:362-3.
15. Walthers L, Salem M, Tessel J, et al. The Inab phenotype: another example found. Transfusion 1983;23(Suppl):423.
16. Lin RC, Herman J, Henry L, et al. A family showing inheritance of the Inab phenotype. Transfusion 1988;28:427-9.
17. Wang L, Uchikawa M, Tsuneyama H, et al. Molecular cloning and characterization of decay-accelerating factor deficiency in Cromer blood group Inab phenotype. Blood 1998;91:680-4.
18. Daniels G, Green CA, Mallinson G, et al. Decay-accelerating factor (CD55) deficiency in Japanese. Transfus Med 1998;8:141-7.
19. Uchikawa M, Tsuneyama H, Ogasawara K, et al. Another example of Inab phenotype in Japanese and production of human monoclonal anti-DAF. Vox Sang 2004;87(S3):41.
20. Hue-Roye K, Powell VI, Patel G, et al. Novel molecular basis of an Inab phenotype. Immunohematology 2005;21:53-5.
21. Matthes T, Tullen E, Poole J, et al. Acquired and transient RBC CD55 deficiency (Inab phenotype) anti-IFC. Transfusion 2002;42:1448-57.
22. Banks J, Poole J, Prowse C, et al. Transient loss of Cromer antigens and anti-IFC in a patient with chronic lymphatic leukemia. Vox Sang 2004;87(S3):37.
23. Judd WJ. Methods in immunohematology. 2nd ed. Durham (NC): Montgomery Scientific Publications; 1994.
24. Nowicki B, Moulds J, Hull R, et al. A hemagglutinin of uropathogenic Escherichia coli recognizes the Dr blood group antigen. Infect Immun 1988;56:1057-60.
25. Judd WJ, Cooling L. Novel application of the gel test: detection of microbial-induced hemagglutination. Vox Sang 2004;87(S3):76.
26. a epitopes of decay accelerating factor: toward the use of recombinant antigens in immunohematology. Blood 1994;84:3205-11.
27. Marsh WL, Nichols ME, Oyen R, et al. Naturally occurring anti-Kell stimulated by E. coli enterocolitis in a 20-day-old child. Transfusion 1978;18:149-54.
28. Medof ME, Walter EI, Rutgers JL, et al. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 1987;165:848-64.
29. Lin F, Spencer D, Hatala DA, et al. Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: role for complement in inflammatory bowel disease. J Immunol 2004;172:3836-41.